Candel Therapeutics (NASDAQ:CADL) Trading 8.4% Higher

Candel Therapeutics, Inc. (NASDAQ:CADL) shares were up 8.4% during mid-day trading on Tuesday . The company traded as high as $9.64 and last traded at $9.59. Approximately 762,586 shares changed hands during trading, a decline of 80% from the average daily volume of 3,890,013 shares. The stock had previously closed at $8.85.

Candel Therapeutics Stock Performance

The company’s 50 day moving average price is $3.85 and its 200-day moving average price is $2.12. The stock has a market cap of $281.47 million, a P/E ratio of -7.38 and a beta of -0.94. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.59 and a current ratio of 2.59.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.22). Equities analysts forecast that Candel Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.